secwatch.observer — SEC 8-K summary
======================================

Issuer:     Dermata Therapeutics, Inc. (DRMA)
CIK:        0001853816
Form:       8-K
Filed at:   2022-11-10T23:59:59+00:00
Accession:  0001654954-22-015036
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Dermata Therapeutics Q3 2022: cash $8.1M; DMT310 rosacea Phase 2 top-line due Dec 2022
--------------------------------------------------------------------------------

- Cash and equivalents $8.1M as of Sep 30, 2022, down from $10.8M at Dec 31, 2021; runway into Q3 2023.
- R&D expenses $1.6M (Q3 2022) vs $0.8M (Q3 2021) due to increased DMT310 program costs.
- G&A expenses flat at $0.9M; stock-based comp $0.2M for G&A and $0.05M for R&D in Q3 2022.
- DMT310 Phase 2 topline results in moderate-to-severe rosacea expected December 2022.
- DMT310 Phase 3 program for moderate-to-severe acne anticipated to start 1H 2023 after FDA meeting.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1853816/000165495422015036/0001654954-22-015036-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1853816/000165495422015036/drma_8k.htm
  HTML page:      https://secwatch.observer/filing/0001654954-22-015036

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer